Suppr超能文献

HIV-HCV 合并感染:马来西亚的流行率和治疗结局。

HIV-HCV Coinfection: Prevalence and Treatment Outcomes in Malaysia.

机构信息

Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, George Town, Malaysia.

University College of Pharmacy, University of the Punjab, Lahore, Pakistan.

出版信息

Intervirology. 2022;65(2):87-93. doi: 10.1159/000518836. Epub 2021 Aug 26.

Abstract

BACKGROUND

Around 130 million infections of hepatitis C virus with 3% overall prevalence are there worldwide. There are approximately 4-5 million persons coinfected with HIV. The main objectives of this study were to determine the prevalence of HCV among HIV-positive individuals and to assess the predictors involved in the outcomes of HIV-HCV coinfected patients.

METHODS

A retrospective, cross-sectional study was conducted on patients enrolled from 2007 to 2012 at Infectious Disease Unit, Hospital Palau Pinang, Pinang, Malaysia. Sociodemographic da%)ta as well as clinical data were collected with the help of a valid data collection form from the patients' records. Data were entered and analyzed by using statistical software SPSS version 20.0, and p < 0.05 was considered significant.

RESULTS

The overall prevalence of hepatitis C among 708 HIV-infected patients was 130 (16.1 including 541 (76.4%) males and 167 (23.6%) females. High prevalence of HIV-HCV coinfection was significantly observed in males (122 [17.2%]) compared to females (8 [1.1%]) (p < 0.001). The main route of transmission among HIV-HCV coinfected patients was heterosexual contact (98 [13.8%]), followed by homosexual contact (4 [0.4%]). The statistically significant predictors involved in treatment outcomes of HIV-HCV coinfected patients are gender (OR = 2.015, p = 0.002) and intravenous drug users (OR = 2.376, p ≤ 0.001).

CONCLUSION

The current study shows that HCV infection has an impact on the recovery of CD4 cells of the patients on HAART. Screening of HCV among HIV patients who were smokers and intravenous drug users should be monitored before starting HAART.

摘要

背景

全球约有 1.3 亿人感染丙型肝炎病毒,总体患病率为 3%。约有 400 至 500 万人同时感染 HIV 和丙型肝炎病毒。本研究的主要目的是确定 HIV 阳性个体中 HCV 的患病率,并评估 HIV-HCV 合并感染患者结局的相关预测因素。

方法

本研究为回顾性、横断面研究,于 2007 年至 2012 年在马来西亚槟城 Palau Pinang 医院传染病科招募患者。借助有效的数据收集表,从患者病历中收集社会人口统计学数据以及临床数据。采用统计软件 SPSS 版本 20.0 录入和分析数据,p<0.05 为差异有统计学意义。

结果

708 例 HIV 感染患者中丙型肝炎的总体患病率为 130 例(16.1%),包括 541 例(76.4%)男性和 167 例(23.6%)女性。与女性(8 例[1.1%])相比,男性(122 例[17.2%])中 HIV-HCV 合并感染的高患病率具有显著差异(p<0.001)。HIV-HCV 合并感染患者的主要传播途径是异性接触(98 例[13.8%]),其次是同性接触(4 例[0.4%])。与 HIV-HCV 合并感染患者治疗结局相关的统计学显著预测因素是性别(OR=2.015,p=0.002)和静脉吸毒者(OR=2.376,p≤0.001)。

结论

本研究表明,HCV 感染会影响接受抗逆转录病毒治疗(HAART)的患者 CD4 细胞的恢复。开始 HAART 前,应监测吸烟和静脉吸毒的 HIV 患者的 HCV 筛查情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验